JAMA Psychiatry
-
anhedonia, anti-inflammatory, Anxiety, C-reactive protein, cytokines, depression, Editor Nina Higson-Sweeney, fatigue, inflammation, interleukin 6, JAMA Psychiatry, major depressive disorder, proof-of-concept, quality of life, randomised controlled trial, somatic symptoms, tocilizumab, topicalTargeting inflammation in depression: a proof-of-concept worth following
Back in the days when we were all cave-dwelling hunters and gatherers,…
-
antidepressants, Bayesian analysis, clinical trials, depression, difficult-to-treat, Editor Eimear Foley, frequentist analysis, JAMA Psychiatry, meta-analysis, non-randomised trials, placebo effect, psilocybin, psychedelic-assisted therapy, psychedelics, systematic review, topical, unblindingIn the Land of the Unblind: are psychedelics really better than antidepressants?
Around 30% of people don’t respond to traditional antidepressants (TADs), such as…
-
#UCLJournalClub, antipsychotic discontinuation, antipsychotics, dose reduction, Editor Dafni Katsampa, first episode psychosis, JAMA Psychiatry, NICE guidelines, psychosis, randomised controlled trial, schizophrenia, secondary care, topical, UCL Division of PsychiatryStop, reduce or stay on antipsychotics after first-episode psychosis?
Recovery from first-episode psychosis (FEP) often brings a sense of relief, but…
-
clinical engagement, digital engagement, digital health, digital innovation, digital mental health, Editor Simon Bradstreet, Health Psychology Review, JAMA Psychiatry, JMIR Mental Health, NPJ Digital Medicine, patient engagement, Systematic Reviews, topicalEngagement with digital mental health interventions remains poorly understood
With recognition of increasing demands on services, health care providers might point…
